Effect of fatty acid chain length and thioesterification on the augmentation of expression of plasminogen activator inhibitor-1
- PMID: 12669679
Effect of fatty acid chain length and thioesterification on the augmentation of expression of plasminogen activator inhibitor-1
Abstract
Background and aim: Concentrations in blood of plasminogen activator inhibitor type 1 (PAI-1) and circulating free (non-esterified) fatty acids (FFA) are increased in diabetes and may accelerate atherosclerosis. We have shown that FFA increase expression of PAI-1 by activation of a transcription factor that binds to the repeated sequence 5'-TG(G/C) 1-2CTG-3'. This study was designed to determine whether FFA chain length, saturation, or both affect agonist properties and whether agonist properties are mediated by activated, thioesterified FFA (fatty acyl-CoA).
Methods and results: Human hepatoma cells were exposed to selected FFA associated with bovine serum albumin (BSA). Triacsin C (5 microM) was used to inhibit production of fatty acyl-CoA. PAI-1 was assayed by enzyme linked immunosorbent assay. Maximal induction of PAI-1 was similar with medium and long chain FFA (fold induction of PAI-1 accumulated in conditioned media compared with control: C10 = 1.8 +/- 0.1, C12 = 2.0 +/- 0.1, C14 = 2.0 +/- 0.2, C16 = 1.4 +/- 0.1, C18 = 1.6 +/- 0.1, C20 = 1.32 +/- 0.1, p < 0.005 for each compared with control). Increased unsaturation did not alter the agonist properties of FFA (fold induction with C16: 0 = 1.4 +/- 0.1, C16: 1 = 1.4 +/- 0.1; C18: 0 = 1.6 +/- 0.1, C18: 1 = 1.5 +/- 0.1, C18: 2 = 1.6 +/- 0.1, C18: 3 = 1.4 +/- 0.1 and C20: 4 = 1.3 +/- 0.1, C20: 5 = 1.4 +/- 0.1, n = 6). However, maximal effects were seen with lower concentrations of longer chain FFA. Triacsin C consistently attenuated effects of FFA.
Conclusions: Longer chain FFA exhibit maximal effects at lower concentrations. Augmented expression of PAI-1 is mediated by the fatty acyl-CoA derivative. These criteria identify targets for therapy designed to normalize expression of PAI-1 and retard progression of atherosclerosis in subjects with elevated concentrations of FFA in blood including those with insulin resistance.
Similar articles
-
Impact of statins on modulation by insulin of expression of plasminogen activator inhibitor type-1.Coron Artery Dis. 2008 Aug;19(5):355-61. doi: 10.1097/MCA.0b013e328300dbe3. Coron Artery Dis. 2008. PMID: 18607173
-
Increased expression of plasminogen activator inhibitor type-1 (PAI-1) in HEPG2 cells induced by insulin mediated by the 3'-untranslated region of the PAI-1 gene and its pharmacologic implications.Coron Artery Dis. 2010 May;21(3):144-50. doi: 10.1097/MCA.0b013e328335790e. Coron Artery Dis. 2010. PMID: 20299979
-
Tumor necrosis factor-alpha-induced production of plasminogen activator inhibitor 1 and its regulation by pioglitazone and cerivastatin in a nonmalignant human hepatocyte cell line.Metabolism. 2006 Nov;55(11):1464-72. doi: 10.1016/j.metabol.2006.06.016. Metabolism. 2006. PMID: 17046548
-
Influence of plasma free fatty acids on lipoprotein synthesis and diabetic dyslipidemia.Exp Clin Endocrinol Diabetes. 2003 Aug;111(5):246-50. doi: 10.1055/s-2003-41284. Exp Clin Endocrinol Diabetes. 2003. PMID: 12951628 Review.
-
Hypothesis: Induction of Autoimmunity in Type 1 Diabetes-A Lipid Focus.Diabetes. 2022 Oct 1;71(10):2067-2074. doi: 10.2337/db22-0240. Diabetes. 2022. PMID: 36126206 Free PMC article. Review.
Cited by
-
Free fatty acids enhance breast cancer cell migration through plasminogen activator inhibitor-1 and SMAD4.Lab Invest. 2009 Nov;89(11):1221-8. doi: 10.1038/labinvest.2009.97. Epub 2009 Sep 14. Lab Invest. 2009. PMID: 19752858 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous